This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Horiguchi, A. Articles by Hayakawa, M. Search for Related Content PubMed PubMed Citation Articles by Horiguchi, A. Articles by Hayakawa, M.

3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitor, Fluvastatin, as a Novel Agent for Prophylaxis of Renal Cancer Metastasis

Department of Urology, National Defense Medical College, Saitama, Japan

Purpose: Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, also called statins, are currently used widely as a safe, effective therapeutic in the treatment of hypercholesterolemia. Recently, statins have been recognized for their activity against cancer. In the present study, we examined the effect of a synthetic statin, fluvastatin, on the development of renal cancer.

Experimental Design: The effects of fluvastatin on cell viability, cell cycle, in vitro angiogenesis, and invasive properties were examined in murine renal cancer cell Renca. The changes in cell cycle-associated proteins, p21^Waf1/Cip1 and p53, and rac1 phosphorylation were analyzed by Western blotting. The prophylactic efficacy of fluvastatin to murine pulmonary metastasis of Renca was examined.

Results: Fluvastatin inhibited in vitro growth of Renca cells in a time- and dose-dependent manner, with up to 70% inhibition at a concentration of 10 µmol/L. This inhibitory effect was due to cell cycle arrest at the G₁ phase and induction of apoptosis accompanied by up-regulation of p21^Waf1/Cip1 and p53. The invasive properties of Renca cells through Matrigel were inhibited by fluvastatin, with decreased phosphorylation of rac1. In vitro angiogenesis was also inhibited by fluvastatin. Furthermore, oral administration at doses of 1 to 10 mg/kg/d, for 12 days after inoculation of Renca cells via the tail vein, significantly decreased the amount of pulmonary metastasis.

Conclusions: Because our results suggest that fluvastatin may effectively inhibit in vitro tumor growth, invasion, angiogenesis, and metastasis of Renca cells, oral administration of fluvastatin could be a novel, safe, and effective agent for preventing metastasis of renal cancer.

This article has been cited by other articles:

				G. Lu, H. Xiao, H. You, Y. Lin, H. Jin, B. Snagaski, and C. S. Yang Synergistic Inhibition of Lung Tumorigenesis by a Combination of Green Tea Polyphenols and Atorvastatin Clin. Cancer Res., August 1, 2008; 14(15): 4981 - 4988. [Abstract] [Full Text] [PDF]

				O. Fromigue, Z. Hamidouche, and P. J. Marie Statin-Induced Inhibition of 3-Hydroxy-3-Methyl Glutaryl Coenzyme A Reductase Sensitizes Human Osteosarcoma Cells to Anticancer Drugs J. Pharmacol. Exp. Ther., May 1, 2008; 325(2): 595 - 600. [Abstract] [Full Text] [PDF]

				G. A. Finlay, A. J. Malhowski, Y. Liu, B. L. Fanburg, D. J. Kwiatkowski, and D. Toksoz Selective Inhibition of Growth of Tuberous Sclerosis Complex 2 Null Cells by Atorvastatin Is Associated with Impaired Rheb and Rho GTPase Function and Reduced mTOR/S6 Kinase Activity Cancer Res., October 15, 2007; 67(20): 9878 - 9886. [Abstract] [Full Text] [PDF]

				V. Khurana, H. R. Bejjanki, G. Caldito, and M. W. Owens Statins Reduce the Risk of Lung Cancer in Humans: A Large Case-Control Study of US Veterans Chest, May 1, 2007; 131(5): 1282 - 1288. [Abstract] [Full Text] [PDF]

				A. Yacoub, W. Hawkins, D. Hanna, H. Young, M. A. Park, M. Grant, J. D. Roberts, D. T. Curiel, P. B. Fisher, K. Valerie, et al. Human Chorionic Gonadotropin Modulates Prostate Cancer Cell Survival after Irradiation or HMG CoA Reductase Inhibitor Treatment Mol. Pharmacol., January 1, 2007; 71(1): 259 - 275. [Abstract] [Full Text] [PDF]

				T.-S. Li, M. Takahashi, R. Suzuki, T. Kobayashi, H. Ito, A. Mikamo, and K. Hamano Pravastatin Improves Remodeling and Cardiac Function After Myocardial Infarction by an Antiinflammatory Mechanism Rather than by the Induction of Angiogenesis Ann. Thorac. Surg., June 1, 2006; 81(6): 2217 - 2225. [Abstract] [Full Text] [PDF]

				K. Hindler, C. S. Cleeland, E. Rivera, and C. D. Collard The Role of Statins in Cancer Therapy. Oncologist, January 1, 2006; 11(3): 306 - 315. [Abstract] [Full Text] [PDF]